Dr. Rothenberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3333 Burnet Ave
# MLC2000
Cincinnati, OH 45229Phone+1 513-636-6771Fax+1 513-636-2511
Education & Training
- Boston Children’s HospitalFellowship, Allergy and Immunology, 1992 - 1994
- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1990 - 1992
- Harvard Medical SchoolClass of 1990
Certifications & Licensure
- OH State Medical License 1997 - 2026
- MA State Medical License 1992 - 1997
- American Board of Allergy and Immunology Allergy & Immunology
- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2000
- Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
Clinical Trials
- Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Start of enrollment: 2001 Dec 01
- A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders Start of enrollment: 2002 Oct 01
- Data Bank for Eosinophilic Disorders Start of enrollment: 2001 May 01
- Join now to see all
Publications & Presentations
PubMed
- 56 citationsAbnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1.Hongyan Zhu, Melissa K. Mingler, Melissa McBride, Andrew J. Murphy, David M. Valenzuela
Psychoneuroendocrinology. 2010-09-01 - 25 citationsA novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cellsMatthew Mahoney, Vishnu C. Damalanka, Michael A Tartell, Dong Hee Chung, André Luiz Lourenço
Biorxiv. 2021-05-06 - 420 citationsTargeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue EosinophiliaMarc E. Rothenberg, James A. MacLean, Eric Pearlman, Andrew D. Luster, Philip Leder
The Journal of Experimental Medicine. 1997-02-17
Journal Articles
- Genetic Variants at the 16p13 Locus Confer Risk for Eosinophilic EsophagitisRobert P Kimberly, Marc E Rothenberg, Patrick M Gaffney, Hugh A Sampson, J Pablo Abonia, Mirna Chehade, Philip E Putnam, Brian P Vickery, Glenn T Furuta, John B Harley, Nature
Press Mentions
- Native American Children, Young Adults with Eosinophilic Esophagitis See Barriers in CareOctober 15th, 2024
- Milk Elimination Diet Shows Promise as First-Line Therapy for Children with EoESeptember 6th, 2024
- Eosinophilic Esophagitis Diet EffectivenessMay 22nd, 2023
- Join now to see all
Grant Support
- Regulation Of Gastrointestinal EosinophilsNational Institute Of Allergy And Infectious Diseases2010–2012
- Role Of Desmoglein-1 In Eosinophilic EsophagitisNational Institute Of Allergy And Infectious Diseases2011
- IL-13 And Eosinophilic EsophagitisNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2011
- IL-13 Associated Eosinophil Lung ResponsesNational Institute Of Allergy And Infectious Diseases2010–2011
- Eosinophilic Esophagitis And Food AllergyNational Institute Of Allergy And Infectious Diseases2010–2011
- Epithelial-Derived Eotaxin 3 In Eosinophilic EsophagitisNational Institute Of Allergy And Infectious Diseases2010
- A Multi-Center Clinical Trial Of 1760 MCG Of Daily Swallowed Fluticasone Vs. PlacNational Institute Of Allergy And Infectious Diseases2010
- IL-13 Associated Eosinophil Lung ResponsesNational Institute Of Allergy And Infectious Diseases2009
- A Multi-Center Clinical Trial Of 1760 MCG Of Daily Swallowed Fluticasone Vs. PlacNational Institute Of Allergy And Infectious Diseases2009
- IL-13 And Eosinophilic EsophagitisNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2009
- Epithelial-Derived Eotaxin 3 In Eosinophilic EsophagitisNational Institute Of Allergy And Infectious Diseases2006–2009
- Clinical Trial: Effect Of Intravenous Anti-Il5 (MEPOLIZUMAB) In HypereosinophiliNational Center For Research Resources2008
- Regulation Of Gastrointestinal EosinophilisNational Institute Of Allergy And Infectious Diseases2004–2008
- Role Of Eotaxins And CCR3 In IL-13 Induced AsthmaNational Heart, Lung, And Blood Institute2004–2008
- Core--Breeding And GenotypingNational Heart, Lung, And Blood Institute2004–2008
- Effect Of Intravenous Anti-Il5 (MEPOLIZUMAB) In Hypereosinophilic SyndromesNational Center For Research Resources2005–2007
- Eosinophil, Chemokine And IL-13 Cooperativity In AsthmaNational Institute Of Allergy And Infectious Diseases2004–2007
- Role Of Arginase In Allergic Airway InflammationNational Institute Of Allergy And Infectious Diseases2003–2007
- Anti-Il 5 For HypereosinophiliaFood And Drug Administration2005
- IV Anti-Il5 (MEPOLIZUMAB) In Hypereosinophilic SyndromesNational Center For Research Resources2004
- Regulation Of Gastrointestinal EosinophilsNational Institute Of Allergy And Infectious Diseases1999–2002
- Mechanisms Of Eosinophilia In Experimental AsthmaNational Institute Of Allergy And Infectious Diseases1998–2002
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: